Prothena Stock Forecast
NASDAQ: PRTAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 8.30 -2.12%
PRTA analyst consensus
Consensus (6 analysts)
none
Avg. price target
$21.40+152.36%
- Strong buy 2
- Buy 1
- Hold 2
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 6 Wall Street analysts covering Prothena (2026-10-08), 3 rate the stock a buy or strong buy, 2 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $21.40, with a high estimate of $36.00 and a low estimate of $8.00. The average target implies upside of 152.4% from the current price of $8.48.
The spread between the highest and lowest targets is 350.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for PRTA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 33% |
| Buy | 1 | 17% |
| Hold | 2 | 33% |
| Sell | 0 | 0% |
| Strong sell | 1 | 17% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $8.00 | -5.66% |
| Average target | $21.40 | +152.36% |
| High target | $36.00 | +324.53% |